S. 1734 · 112th Congress
Generating Antibiotic Incentives Now Act of 2011
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 112th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
BlumenthalSponsor14 cosponsors · 7 D, 7 R
R
Alexander
MB
D
Bennet
BC
D
Casey
BC
R
Corker
CC
D
Coons
OH
R
Hatch
PR
R
Roberts
JK
D
Kerry
SC
R
Chambliss
JI
R
Isakson
JT
D
Tester
MB
D
Begich
TC
D
Carper
KA
R
Ayotte6 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Generating Antibiotic Incentives Now Act of 2011 - Amends the Federal Food, Drug, and Cosmetic Act to extend the exclusivity period for a new prescription drug by five years for a drug that the Secretary of Health and Human Services (HHS) determines to be a qualified infectious disease product.
What it does: CRS summary · Introduced in Senate · Oct 19, 2011
Generating Antibiotic Incentives Now Act of 2011 - Amends the Federal Food, Drug, and Cosmetic Act to extend the exclusivity period for a new prescription drug by five years for a drug that the Secretary of Health and Human Services (HHS) determines to be a qualified infectious disease product. Defines "qualified infectious disease product" to mean an antibiotic drug for treating, detecting, preventing, or identifying a qualifying pathogen (certain pathogens that are resistant to antibiotics). Excludes drugs that are: (1) a supplement to a new drug application for which an extension is in effect or has expired; or (2) a subsequent application for a change that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or a modification to the structure of the product that does not result in a change in safety or effectiveness.
Extends such period of exclusivity an additional six months for a sponsor or manufacturer of a qualified infectious disease product that identifies a companion diagnostic test.
Requires the Secretary to give priority review to any drug determined to be a qualified infectious disease product.
Includes qualified infectious disease products as fast track products for which the Secretary shall facilitate development and expedite review.
Directs the Comptroller General to study the need for incentives to encourage the research, development, and marketing of qualified infectious disease biological products.
Requires the Secretary to: (1) review Food and Drug Administration (FDA) guidelines for clinical trials of antibiotic drugs; and (2) revise such guidelines, as appropriate, to reflect developments in scientific and medical information and technology and to ensure clarity regarding the procedures and requirements for approval of an antibiotic drug.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Generating Antibiotic Incentives Now Act of 2011
Latest action (Oct 19, 2011): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Policy area: Health · Origin: Senate · Introduced: Oct 19, 2011
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.